Diazepam Stada

Diazepam Stada is an oral dosage form that contains the active ingredient diazepam, a benzodiazepine classified under ATC code N05BA01. Marketed in the European Union, this prescription product is supplied in tablet form with strengths that may vary according to national labeling. It acts as a positive allosteric modulator of the GABA‑A receptor, enhancing inhibitory neurotransmission in the central nervous system and is commonly used in clinical practice.

Diazepam Stada is prescribed for several central nervous system conditions where its anxiolytic, anticonvulsant, muscle‑relaxant, and sedative properties are beneficial.

- Management of generalized anxiety disorder and other anxiety‑related conditions. - Adjunctive therapy for certain seizure disorders, including status epilepticus. - Relief of acute muscle spasm associated with musculoskeletal injuries. - Treatment of symptoms associated with alcohol withdrawal syndrome. - Short‑term sedation prior to medical procedures when indicated.

Side effects of diazepam may vary in frequency and severity, reflecting its central nervous system activity.

Common: - Drowsiness or fatigue - Dizziness or light‑headed feeling - Impaired coordination or gait instability - Memory disturbances, such as difficulty recalling recent events

Serious: - Respiratory depression, especially when combined with other depressants - Severe hypotension or cardiovascular collapse - Paradoxical reactions including agitation, aggression, or hallucinations - Dependence, withdrawal syndrome, or tolerance with prolonged use

Clinicians should evaluate patient‑specific factors before initiating diazepam therapy to minimize risks.

- Assess for a history of respiratory disorders, such as chronic obstructive pulmonary disease or sleep apnea. - Use caution in patients with hepatic impairment, as metabolism may be reduced. - Evaluate for potential dependence, especially in individuals with substance‑use disorders. - Avoid abrupt discontinuation after prolonged therapy to prevent withdrawal symptoms. - Consider dose adjustment in elderly patients due to increased sensitivity. - Review pregnancy and lactation status, as safety data are limited.

Diazepam can interact with a range of medications, altering its efficacy or safety profile.

Avoid: - Concomitant use with other central nervous system depressants (e.g., opioids, barbiturates, alcohol) due to additive sedation and respiratory risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) which can increase diazepam plasma concentrations. - CYP2C19 inhibitors (e.g., fluoxetine, omeprazole) that may elevate active metabolite levels.

Use with caution: - CYP3A4 inducers (e.g., carbamazepine, rifampin) which may reduce therapeutic effect. - Other benzodiazepines or sedative‑hypnotics, requiring dose adjustments. - Antidepressants or antipsychotics that may potentiate central effects.